WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004009784) NOVEL INHIBITORS OF KINASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/009784    International Application No.:    PCT/US2003/022826
Publication Date: 29.01.2004 International Filing Date: 18.07.2003
Chapter 2 Demand Filed:    05.02.2004    
IPC:
A61K 31/53 (2006.01), A61K 45/06 (2006.01), C07D 487/04 (2006.01)
Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P. O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US) (For All Designated States Except US).
BHIDE, Rajeev [US/US]; (US) (For US Only).
CAI, Zhen-Wei [US/US]; (US) (For US Only).
QIAN, Ligang [US/US]; (US) (For US Only).
BARBOSA, Stephanie [US/US]; (US) (For US Only).
LOMBARDO, Louis [US/US]; (US) (For US Only).
ROBL, Jeffrey [US/US]; (US) (For US Only)
Inventors: BHIDE, Rajeev; (US).
CAI, Zhen-Wei; (US).
QIAN, Ligang; (US).
BARBOSA, Stephanie; (US).
LOMBARDO, Louis; (US).
ROBL, Jeffrey; (US)
Agent: KORSEN, Elliott; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US)
Priority Data:
60/397,256 19.07.2002 US
60/447,213 13.02.2003 US
Title (EN) NOVEL INHIBITORS OF KINASES
(FR) NOUVEAUX INHIBITEURS DE KINASES
Abstract: front page image
(EN)The present invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula (I) compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
(FR)La présente invention concerne des composés de formule (I) et des sels pharmaceutiquement acceptables de ces derniers. Les composés de formule (I) inhibent l'activité tyrosine kinase de récepteurs du facteur de croissance tels que VEGFR-2 et FGFR-1, ce qui les rend utiles en tant qu'agents anticancéreux. Les composés de formule (I) sont également utiles pour le traitement d'autres maladies associées aux voies de transduction du signal fonctionnant à travers des récepteurs du facteur de croissance.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)